文献速递眼底病与葡萄膜炎

全视网膜光凝与玻璃体内注射贝伐珠单抗及一种改良联合方案治疗增殖性糖尿病视网膜病变的比较:一项随机三臂临床试验(CTPDR研究)

PANRETINAL PHOTOCOAGULATION VERSUS INTRAVITREAL BEVACIZUMAB VERSUS A PROPOSED MODIFIED COMBINATION THERAPY FOR TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY: A Randomized Three-Arm Clinical Trial (CTPDR Study).
PubMed 文献 · Retina · 2022-01-01

该随机三臂临床试验纳入207只未治疗过的增殖性糖尿病视网膜病变眼,比较全视网膜光凝、玻璃体内注射贝伐珠单抗(IVB,每月一次共四次)及改良联合方案(两次双月IVB注射联合改良激光治疗)的安全性与疗效。1年随访时三组最终最佳矫正视力差异无统计学意义(P=0.77),改良联合组最终渗漏面积最低(P=0.006)。作者认为光凝联合IVB方案可用于增殖性糖尿病视网膜病变,尤其适用于基线存在糖尿病黄斑水肿者。

要点

  • 三组最终最佳矫正视力差异无统计学意义(P=0.77)。
  • 改良联合组最终渗漏面积最低(P=0.006)。
  • 作者认为光凝联合IVB方案可用于增殖性糖尿病视网膜病变,尤其基线有糖尿病黄斑水肿者。

核心结论

  • 作者认为光凝联合IVB方案可用于增殖性糖尿病视网膜病变,尤其适用于基线存在糖尿病黄斑水肿者。

研究设计与样本

  • 随机三臂临床试验,纳入207只未治疗过的增殖性糖尿病视网膜病变眼,随机分为全视网膜光凝组、IVB组(每月一次共四次)和改良联合组(两次双月IVB注射联合改良激光治疗),随访1年。

主要发现

  • 三组最终最佳矫正视力差异无统计学意义(P=0.77)。
  • 改良联合组最终渗漏面积最低(P=0.006)。
  • IVB组与改良联合组最终视野平均偏差差异无统计学意义(平均差=0.25,P=0.23,95%CI 0.12-1.38)。
  • IVB组与改良联合组新发糖尿病黄斑水肿率差异无统计学意义(平均差=1.5%,P=0.31,95%CI 1.1-1.88)。
  • 全视网膜光凝组、IVB组和改良联合组的平均IVB注射总次数分别为3.5、7.4和6.2次(P=0.002);IVB组患者就诊次数更多(P=0.001)。

关键数值与推荐

  • 亚组分析中,合并糖尿病黄斑水肿的眼最终渗漏面积差异有统计学意义(P=0.005)。

临床怎么用

  • 作者认为光凝联合IVB方案可用于增殖性糖尿病视网膜病变,尤其适用于基线存在糖尿病黄斑水肿者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare safety and therapeutic effect of three treatment protocols on patients with naive proliferative diabetic retinopathy. METHODS: A total of 207 eyes with proliferative diabetic retinopathy were randomly divided into three groups: full panretinal photocoagulation group; intravitreal bevacizumab (IVB) group with four monthly IVB injections; and modified combination group with two bimonthly IVB injections and a modified laser therapy. The best-corrected visual acuity and area of neovascularization leakage were compared at 1-year follow-up. RESULTS: The difference in final best-corrected visual acuity was not significant between the groups (P = 0.77). The modified combination group had the lowest final leakage area (P = 0.006). The difference in final mean deviation of visual field was not significant between IVB and modified combination groups (mean difference = 0.25, P = 0.23, 95% confidence interval, 0.12-1.38). There was no difference in rate of new-onset diabetic macular edema between IVB and modified combination groups (mean difference = 1.5%, P = 0.31, 95% confidence interval, 1.1-1.88). Mean of total IVB injections were 3.5, 7.4, and 6.2 for panretinal photocoagulation, IVB, and modified combination groups, respectively (P = 0.002). Patients in the IVB group underwent more visits (P = 0.001). In subgroup analysis, the difference in the final leakage area was significant for the eyes with diabetic macular edema (P = 0.005). CONCLUSION: A combination protocol of photocoagulation and IVB can be recommended for proliferative diabetic retinopathy, especially with baseline diabetic macular edema.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Shahraki T, Arabi A, Nourinia R, et al. PANRETINAL PHOTOCOAGULATION VERSUS INTRAVITREAL BEVACIZUMAB VERSUS A PROPOSED MODIFIED COMBINATION THERAPY FOR TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY: A Randomized Three-Arm Clinical Trial (CTPDR Study). Retina. 2022. PMID: 35594075. doi:10.1097/IAE.0000000000003450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。